Views on Suven Pharma & Cohance Lifesciences Merger by Mr. Manmohan Tiwana, MD & CEO at Wodehouse Capital
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
Below the Views on Suven Pharma & Cohance Lifesciences Merger by Mr. Manmohan Tiwana, MD & CEO at Wodehouse Capital
"Cohance Lifesciences being an integrated API and CDMO manufacturer with a strong vintage shall demonstrate strong synergies post its merger with Suven Pharma, a world-class manufacturer of pharmaceuticals and fine chemical intermediates. This merger will provide operational efficiences and end-to-end product development and delivery for the end-customer with strong raw material sourcing. This merger will create tremendous shareholder value. Also, merging synergistic privately owned companies with their publicly owned company provides private equity firms a clear path to exit."
Above views are of the author and not of the website kindly read disclaimer
Tag News
China Unveils Policies to Boost Trade Amid Tariff Worries by Amit Gupta, Kedia Advisory
More News
Comment on JLL Report - Residential sales set to soar: Projected 260k units by end of 2023, ...
